Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 153 Lung Neoplasms 69 Carcinoma, Hepatocellular 63 Small Cell Lung Carcinoma 48 Breast Neoplasms 47 Squamous Cell Carcinoma of Head and Neck 35 Urinary Bladder Neoplasms 30 Colorectal Neoplasms 30 Biliary Tract Neoplasms 29 Neoplasms 28 Neoplasm Metastasis 28 Cholangiocarcinoma 26 Triple Negative Breast Neoplasms 25 Pancreatic Neoplasms 25 Ovarian Neoplasms 24 Liver Neoplasms 18 Head and Neck Neoplasms 18 Carcinoma, Renal Cell 17 Recurrence 16 Melanoma 14 Stomach Neoplasms 13 Prostatic Neoplasms 13 Carcinoma 13 Endometrial Neoplasms 12 Uterine Cervical Neoplasms 11 Esophageal Neoplasms 11 Carcinoma, Transitional Cell 11 Lymphoma, Large B-Cell, Diffuse 10 Gallbladder Neoplasms 9 Adenocarcinoma Of Esophagus 9

Interventions

pembrolizumab 2 atezolizumab 2 trastuzumab deruxtecan 1 toripalimab 1 pertuzumab 1 fludarabine 1 durvalumab 1 cabazitaxel 1 XRP6258 1 Trastuzumab 1 S-Adenosylmethionine 1 Ramucirumab 1 Paclitaxel 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 Irinotecan 1 Fluorouracil 1 Etoposide 1 Cyclophosphamide 1 Cetuximab 1 Carboplatin 1 Capecitabine 1 Bevacizumab 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Solid Cancer × durvalumab × Clear all

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡